Extended Data Fig. 2: MCSP defines a subset of melanoma DCC linked to systemic progression.
a, Schematic overview of analyzed patient samples and exclusion criteria. Note reference to individual figure panels. b, left panel: Melanoma patients with IC positive SLNs (n = 165). Percentage and number of patients with SLNs single-positive for gp100+ DCCs (79/165) or MCSP+ DCCs (23/165) or double-positive for gp100+ DCCs and MCSP+ DCCs (63/165). Right panel: Percentage and number of patients with Gp100+ DCCs in their SLNs, in whom MCSP+ DCCs were co-detected or not. c, Impact of LN involvement at diagnosis on metachronous distant metastasis. SLN+: patients with gp100+ and/or MCSP+MT+ cells in the SLN or with a positive SLN by histopathology. Patients without LN involvement: patients lacking gp100+ or MCSP+MT+ cells in SLN, a negative SLN by histopathology and without evidence of LN involvement at any time during the disease. P values in c, Fisher’s exact test (two-sided). See Table 1 for baseline characteristics of the study cohort.
